BioLargo Engineering, Science & Technologies, Inc. (BLEST), a subsidiary of BioLargo, Inc., has been awarded a $1.2 million contract to design a pilot‑scale minerals processing facility for a private client in the western United States. The project will remediate a legacy mineral waste deposit and convert non‑hazardous waste materials into valuable commercial products using BLEST’s proprietary and patented processes.
The design phase is expected to take roughly six months, with the overall development program projected to span two to three years. The facility will support the remediation and beneficial reuse of the waste deposit, positioning the client to turn an environmental liability into an economic opportunity. BLEST’s technology focuses on converting waste streams into high‑value products, a capability that has attracted interest from a range of industries seeking sustainable waste‑to‑value solutions.
This contract follows a history of similar wins, including several awards totaling more than $1.2 million in 2021 for projects such as a resin manufacturing facility, a dairy farm, and a U.S. Air Force base. In 2025, BLEST’s engineering services revenue grew 98% to $1.998 million, underscoring the company’s expanding footprint in clean‑technology engineering. The new contract adds a significant revenue stream that will help BioLargo, Inc. diversify its income and support its broader strategy of commercializing environmental remediation technologies.
President and CEO Dennis P. Calvert said the project “exemplifies the growing importance of waste‑to‑value solutions in modern environmental management. By transforming legacy waste streams into commercially valuable products, we are helping our clients turn environmental liabilities into economic opportunities.” The contract signals confidence in BLEST’s technology and provides a platform for future scale‑up and commercialization.
Analysts have responded positively to the announcement. While the company’s stock has traded in a low range of $0.14–$0.15 in mid‑April, one analyst has maintained a “Strong Buy” rating with a price target of $0.32, and another has issued a “Hold” rating with a target of $0.17. The contract is viewed as a positive development that could strengthen BioLargo’s engineering services segment and support its long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.